Skip to main content
Clinical Trials/NL-OMON28309
NL-OMON28309
Completed
Not Applicable

A randomised, double blind, parallel, placebo controlled, drug-drug interaction study to investigate the safety, tolerability and pharmacokinetics of multiple doses of HTL0018318 given alone and in combination with donepezil at steady state in elderly volunteers.

Heptares Therapeutics Ltd.0 sites36 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Drug-Drug interaction, M1 agonist, Alzheimer, donepezil
Sponsor
Heptares Therapeutics Ltd.
Enrollment
36
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

ot applicable

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Heptares Therapeutics Ltd.

Eligibility Criteria

Inclusion Criteria

  • 1\. Elderly male or female subjects aged between 65 and 80 (inclusive) years old;
  • 2\. Healthy subjects as defined by the absence of evidence of any active or chronic disease following detailed medical and surgical history review and a complete physical examination including vital signs, 12\-lead ECG, haematology, blood chemistry, and urinalysis;

Exclusion Criteria

  • Subjects must meet none of the following exclusion criteria at screening:
  • 1\. Legal incapacity or inability to understand or comply with the requirements of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials